NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 7 நாட்களுக்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Q2 FY27 PAT Jumps 45.2% YoY to ₹15.4 Cr; Total Income at ₹138.6 Cr
GPT Healthcare reported strong growth for Q2 FY27, with Total Income increasing 15.2% YoY to ₹138.6 crore and Profit After Tax surging 45.2% YoY to ₹15.4 crore. Operating EBITDA expanded 23.9% YoY to ₹29.8 crore, driven by a 150 bps margin improvement to 21.5%. For H1 FY27, net profit stood at ₹28.1 crore, already exceeding the entire TTM PAT of ₹17 crore. Operational performance gained momentum as network occupancy rose to 50.3% in Q2, with ARPOB increasing 7.1% YoY to ₹40,721.
உச்சம் நம்பிக்கை
என்ன மாறியதுGPT Healthcare reported its Q2 & H1 FY27 results via a press release, demonstrating substantial profit growth and margin expansion across its hospital network.
ஏன் இது முக்கியம்The company's H1 FY27 PAT of ₹28.1 crore comfortably surpasses its previous TTM PAT of ₹17 crore, demonstrating strong operating leverage from increased bed occupancy (50.3%) and higher ARPOB.
Q2 FY27 Total Income: ₹138.6 கோடிQ2 FY27 PAT: ₹15.4 கோடிQ2 FY27 EBITDA Margin: 21.5%H1 FY27 PAT vs TTM PAT: 165.3%Q2 FY27 ARPOB: ₹40,721Q2 Network Occupancy: 50.3%
📅 குறுகிய காலம்The sharp 45.2% PAT expansion and margin improvement to 21.5% are likely to provide near-term earnings support following a 12.8% 3-month share price decline.
📈 நீண்ட காலம்Operating leverage is playing out as mature and new hospitals (Raipur) ramp up towards higher occupancy; ongoing pipeline additions like Jamshedpur (Q4 FY27) support capacity growth.
⚠ அபாய எச்சரிக்கைகள்
Geographic concentration primarily in Eastern India.
Regulatory caps on medical procedures and pharmaceutical/device procurement costs.
👀 கவனிக்க வேண்டியவை
Track the ramp-up and occupancy levels at the newer Raipur facility, and monitor project execution progress at the upcoming Jamshedpur facility scheduled for Q4 FY27.
GPT Healthcare Declares ₹1.00 Interim Dividend for FY 2026-27; Record Date Nov 12, 2026
GPT Healthcare Limited has declared an interim dividend of ₹1.00 per equity share (10% of face value of ₹10) for FY 2026-27. At the current share price of ₹144.2, this represents an interim dividend yield of approximately 0.69%. The payout amounts to roughly ₹8.2 crore on its ~8.2 crore share base, representing about 48% of its TTM net profit of ₹17 crore. The record date to determine shareholder eligibility is November 12, 2026, with payout scheduled on or before December 4, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe Board declared a ₹1.00 per share interim dividend and fixed the schedule for shareholder record and payment dates.
ஏன் இது முக்கியம்Demonstrates continued cash return to shareholders, absorbing roughly half of annualised TTM net earnings while the company executes capex on its network.
Interim Dividend per share: ₹ 1.00Dividend rate on Face Value: 10%ரெக்கார்ட் தேதி: நவம்பர் 12, 2026Payment deadline: டிசம்பர் 4, 2026Interim dividend yield: ~0.69%
📅 குறுகிய காலம்Stock will trade ex-dividend ahead of November 12, 2026; minor routine price adjustment expected corresponding to the ₹1.00 payout.
📈 நீண்ட காலம்Limited structural impact; dividend policy indicates steady operational cash flow despite ongoing expansion at Raipur and planned Ranchi projects.
👀 கவனிக்க வேண்டியவை
Investors seeking dividend eligibility must hold shares before the ex-dividend date associated with the November 12, 2026 record date. Monitor Raipur hospital bed occupancy ramp-up in upcoming quarterly updates.
66% PAT Growth in Q1 FY27; GPT Healthcare Reports 18.2% Revenue Increase
GPT Healthcare reported a strong Q1 FY27 with total income rising 18.2% and PAT surging 66% YoY. While overall network occupancy stood at 45.5%, mature hospitals maintained a healthier 58.07%, reflecting the initial ramp-up phase of the newly commissioned Raipur facility which reached 17% occupancy. ARPOB improved to ₹42,350, driven by a shift toward high-end tertiary care and robotic surgeries. Management expects the Dumdum facility to reach 70% occupancy by Q3 FY27 and is targeting approximately 10 liver transplants annually at the Raipur unit.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from a pure capacity addition phase to an operational ramp-up phase, specifically showing traction in robotic surgeries and organ transplants.
ஏன் இது முக்கியம்The significant jump in PAT relative to revenue suggests improving operational leverage and a better case mix, which is critical for a mid-sized hospital chain to improve its 16.8% OPM.
PAT Growth (YoY): 66%Revenue Growth (YoY): 18.2%Network ARPOB: ₹42,350Cash and Insurance Payer Mix: 90%Raipur Occupancy: 17%Mature Hospital Occupancy: 58.07%
📅 குறுகிய காலம்The stock may see positive interest due to the high PAT growth and successful clinical milestones like the first liver transplant in Raipur.
📈 நீண்ட காலம்Long-term value depends on the Raipur facility reaching monthly breakeven (expected by month 13-14) and the successful commissioning of the Ranchi unit in FY28.
⚠ அபாய எச்சரிக்கைகள்
Low occupancy at the new Raipur unit (17%) acting as a drag on overall margins
Geographic concentration in West Bengal and Tripura
Geopolitical issues impacting patient inflow from Bangladesh at the Agartala unit
👀 கவனிக்க வேண்டியவை
Monitor the occupancy ramp-up at the Raipur facility and the management's ability to sustain ARPOB growth through complex surgeries. Investors should also track the execution timeline for the Ranchi hospital planned for FY28.
GPT Healthcare Declares ₹1.50 Final Dividend at 37th AGM; Total FY26 Dividend at ₹2.50
GPT Healthcare concluded its 37th Annual General Meeting on August 6, 2026, where shareholders approved a final dividend of ₹1.50 per share. This brings the total dividend for FY25-26 to ₹2.50 per share, which is notable given the FY26 EPS of ₹2.08. The meeting also covered the adoption of FY26 audited financials (Revenue: ₹227.27 Cr, PAT: ₹17.05 Cr) and the re-appointment of several directors. Additionally, shareholders considered resolutions for remuneration and consultancy fees for three related-party medical professionals.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has finalized its dividend distribution for FY26 and obtained shareholder approval for its annual financial accounts and board composition.
ஏன் இது முக்கியம்The total dividend of ₹2.50 per share represents a high payout ratio relative to the FY26 EPS of ₹2.08, signaling a strong commitment to returning cash to shareholders despite ongoing expansion plans in Raipur and Ranchi.
Final Dividend: ₹1.50 per shareTotal FY26 Dividend: ₹2.50 per shareDividend vs FY26 EPS: 120.19%Shareholder Attendance: 65.60%FY26 Revenue: ₹227.27 கோடி
📅 குறுகிய காலம்The confirmation of the final dividend is likely to be viewed positively by retail investors in the coming days.
📈 நீண்ட காலம்Limited structural impact as this was a routine AGM; however, the high dividend payout suggests management confidence in cash flows despite the capital-intensive nature of hospital expansions.
⚠ அபாய எச்சரிக்கைகள்
Dividend payout exceeds FY26 earnings per share
Multiple related-party remuneration approvals
👀 கவனிக்க வேண்டியவை
Investors should monitor the final voting results to be published within 2 working days to confirm the approval of related-party remuneration and director re-appointments.
GPT Healthcare Q1 FY27: PAT Surges 65.7% YoY to ₹12.7 Cr with 20.4% EBITDA Margin
GPT Healthcare reported a strong start to FY27 with total income rising 18% YoY to ₹128.2 Cr. Profitability saw a significant boost as PAT jumped 65.7% YoY to ₹12.7 Cr, supported by EBITDA margins expanding 300 bps to 20.4%. While overall occupancy stood at 45.5% due to the new Raipur facility, mature hospitals maintained a higher occupancy of 58.07%. The company is aggressively expanding, with the Jamshedpur hospital on track for Q4 FY27 and a 7th facility in the works to take total capacity beyond 1,000 beds.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has demonstrated significant margin expansion and profit growth YoY, while progressing on its geographic diversification strategy beyond West Bengal.
ஏன் இது முக்கியம்The sharp increase in PAT and margins indicates improving operational leverage and a successful shift toward high-value specialties like robotic surgeries and transplants, which command better realizations.
Q1 FY27 Total Income: ₹128.2 கோடிPAT Growth (YoY): 65.7%EBITDA லாப வரம்பு: 20.4%ARPOB: ₹42,350Current Bed Capacity: 719 bedsTarget Bed Capacity: >1,000 beds
📅 குறுகிய காலம்The stock is likely to react positively to the strong YoY earnings growth and margin expansion, reflecting improved operational efficiency.
📈 நீண்ட காலம்The structural shift toward a 1,000+ bed network and expansion into underserved markets like Raipur, Jamshedpur, and Ranchi provides a clear growth runway for the next 2-3 years.
⚠ அபாய எச்சரிக்கைகள்
Occupancy dilution from new facilities (currently 45.5% overall)
Execution risks in commissioning the Jamshedpur and Ranchi projects
👀 கவனிக்க வேண்டியவை
Investors should monitor the occupancy ramp-up at the Raipur facility and the timely commissioning of the Jamshedpur hospital in Q4 FY27. The ability to maintain 20%+ EBITDA margins as new capacity comes online will be a key performance indicator.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
65.7% PAT Growth in Q1 FY27; GPT Healthcare Targets 1,000+ Beds in Two Years
GPT Healthcare reported a strong Q1 FY27 with revenue growing 17.8% YoY to ₹126.2 Cr. Profit After Tax (PAT) surged 65.7% YoY to ₹12.7 Cr, driven by an 11% improvement in ARPOB to ₹42,350 and higher clinical complexity. While overall occupancy stood at 45.5%, mature hospitals maintained 58.07% occupancy. The newly commissioned Raipur facility (158 beds) is on track for operational breakeven by Q3 FY27, supporting the company's roadmap to reach a 1,000-bed capacity by FY27-28.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has demonstrated significant margin recovery (20.4% vs 18.8% in FY26) as new capacities begin to stabilize and high-acuity procedures increase.
ஏன் இது முக்கியம்The strong earnings growth indicates that the company is successfully absorbing the costs of its recent Raipur expansion while improving realizations at mature units through robotic and specialized care.
Q1 FY27 Revenue: ₹126.2 கோடிYoY PAT Growth: 65.7%ARPOB: ₹42,350Current Bed Capacity: 719 bedsMature Hospital Occupancy: 58.07%
📅 குறுகிய காலம்The stock may react positively to the sharp jump in PAT and EBITDA margins, reflecting improved operational efficiency.
📈 நீண்ட காலம்The structural growth story depends on the successful transition to a 1,000-bed network and reducing geographic concentration in West Bengal through the Raipur and Ranchi projects.
⚠ அபாய எச்சரிக்கைகள்
Low occupancy at Raipur (17.4%) remains a near-term drag on overall returns
Geographic concentration in Eastern India
Regulatory risks regarding price caps on medical procedures
👀 கவனிக்க வேண்டியவை
Investors should monitor the occupancy ramp-up at the Raipur facility and the execution timeline for the Ranchi hospital (planned for FY28) to validate the 1,000-bed expansion strategy.
₹1.50 Final Dividend: GPT Healthcare Sets July 30 as Record Date for 37th AGM
GPT Healthcare has scheduled its 37th Annual General Meeting for August 6, 2026, and confirmed a final dividend of ₹1.50 per share (15% of face value) for FY25-26. The record date for dividend eligibility and e-voting is July 30, 2026, with payments to be completed by September 4, 2026. This dividend represents a payout of approximately 72% of the TTM EPS of ₹2.08. Investors can now access the full Annual Report for FY25-26 via the company's website.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has formalized the dates for its annual shareholder meeting and the record date for its final dividend payment.
ஏன் இது முக்கியம்This is a routine but necessary administrative step that confirms the timing of cash returns to shareholders and provides the full financial disclosures for the previous fiscal year.
Final Dividend: ₹1.50 per shareடிவிடெண்ட் ஈல்ட்: 0.95%ரெக்கார்ட் தேதி: ஜூலை 30, 2026AGM Date: ஆகஸ்ட் 6, 2026TTM EPS: ₹2.08
📅 குறுகிய காலம்The stock may see minor activity around the record date of July 30 as it trades ex-dividend.
📈 நீண்ட காலம்Limited structural impact from this filing; long-term value depends on the successful ramp-up of the Raipur facility and the asset-light expansion in Ranchi by FY28.
👀 கவனிக்க வேண்டியவை
Investors should review the Annual Report for updates on the Raipur hospital's breakeven timeline and the Ranchi expansion project. Ensure bank details are linked to KYC-compliant folios by July 30 to receive the dividend.
GPT Healthcare reported a 24% YoY revenue growth in Q4 FY26, reaching ₹128 crores, while full-year revenue stood at ₹478.5 crores. Mature hospitals delivered a strong EBITDA margin of 23.06%, though consolidated margins were diluted to 18.8% due to the newly commissioned Raipur facility's ₹13.8 crore EBITDA loss. Operational metrics showed improvement with ARPOB rising to ₹39,200 and network occupancy (excluding Raipur) at 55.9%. Management expects the Raipur facility to achieve operational breakeven by Q3 FY27 as occupancy continues to scale.
முக்கிய அம்சங்கள்
Full-year FY26 revenue reached ₹478.5 crores with a consolidated PAT of ₹42.2 crores.Mature hospital EBITDA margin improved by 94 basis points to 23.06% excluding the Raipur facility.ARPOB increased from ₹37,000 to ₹39,200, driven by a better specialty mix and complex tertiary procedures.Raipur Hospital reached 14.26% occupancy in Q4 FY26 and is targeted to break even by Q3 FY27.Expansion remains on track with a 150-bed tertiary care hospital under development in Jamshedpur.
👀 கவனிக்க வேண்டியவை
Investors should focus on the margin expansion potential as the Raipur facility moves toward breakeven in late FY27. The strong performance of mature assets and the company's focus on underserved Eastern Indian markets support a positive long-term growth thesis.
GPT Healthcare Q4 Revenue Up 24.3% to ₹128 Cr; FY26 PAT Dips 15% on Expansion
GPT Healthcare reported a strong Q4 FY26 with revenue growing 24.3% YoY to ₹128 crore and PAT increasing 13% to ₹14.7 crore. However, full-year FY26 performance saw a 15.4% decline in PAT to ₹42.2 crore, primarily due to the commencement and gestation costs of the new Raipur facility. Operational metrics remain healthy with an ARPOB of ₹39,243 and occupancy at 55.9% for mature hospitals. The company is continuing its expansion strategy with a new 150-bed facility planned in Jamshedpur by FY27.
முக்கிய அம்சங்கள்
Q4 Revenue grew 24.3% YoY to ₹128.0 Cr, while Q4 PAT rose 13% to ₹14.7 Cr.Full-year FY26 Revenue increased 15.1% to ₹478.5 Cr, but PAT fell 15.4% to ₹42.2 Cr.EBITDA margins for FY26 contracted to 18.84% from 22.10% in FY25 due to Raipur facility costs.Operational ARPOB stood at ₹39,243 with 800+ robotic surgeries completed at Salt Lake.Signed MoU for a new 150-bed hospital in Jamshedpur, targeted for FY27 completion.
👀 கவனிக்க வேண்டியவை
Investors should monitor the ramp-up of the Raipur facility and the execution of the Jamshedpur expansion, as these will drive future growth despite short-term margin pressure. The strong Q4 recovery suggests the business is successfully absorbing expansion costs.
GPT Healthcare reported a 15.14% YoY revenue growth to ₹478.5 Cr for FY26, supported by a rise in ARPOB to ₹39,243. However, consolidated PAT declined by 15.43% to ₹42.2 Cr, largely due to the operational drag from the new Raipur hospital which incurred an EBITDA loss of ₹13.8 Cr. While mature hospitals maintained a strong EBITDA margin of 23.06%, the overall margin compressed to 18.84%. The company is continuing its expansion with a 150-bed Jamshedpur project to reach a total capacity of 869 beds.
முக்கிய அம்சங்கள்
FY26 Revenue increased 15.14% YoY to ₹478.5 Cr, driven by improved clinical mix and ARPOB growth.Mature hospitals delivered a resilient EBITDA of ₹103.9 Cr with a 23.06% margin.New Raipur hospital impacted overall performance with an EBITDA loss of ₹13.8 Cr and low occupancy of 12.35%.Overall network occupancy stood at 45.87%, but excluding Raipur, it remained healthy at 55.90%.The 150-bed Jamshedpur tertiary care project is progressing as planned to expand regional footprint.
👀 கவனிக்க வேண்டியவை
Investors should focus on the occupancy ramp-up at the Raipur facility, as its path to breakeven is critical for overall margin recovery. While the core mature portfolio is performing well, short-term profitability will remain under pressure due to expansion-related depreciation and finance costs.
GPT Healthcare Recommends ₹1.50 Final Dividend for FY 2025-26
GPT Healthcare Limited has recommended a final dividend of ₹1.50 per equity share for the financial year ended March 31, 2026, which is 15% of the face value of ₹10. The dividend is subject to shareholder approval at the 37th Annual General Meeting (AGM) scheduled for August 6, 2026. The company has established July 30, 2026, as the record date for determining dividend eligibility. If approved, the payout will be completed within 30 days from the date of the AGM.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹1.50 per equity share (15% payout on ₹10 face value)Record date for dividend entitlement is fixed as July 30, 202637th Annual General Meeting (AGM) scheduled for August 6, 2026Book closure period set from July 31, 2026, to August 6, 2026Dividend to be paid within 30 days of shareholder approval
👀 கவனிக்க வேண்டியவை
Investors seeking dividend income should ensure they hold the stock before the record date of July 30, 2026. The 15% dividend payout indicates a healthy cash flow and a commitment to shareholder returns.
GPT Healthcare reported a 12.12% YoY revenue growth for 9M FY26, reaching ₹350.5 crores, with EBITDA margins stable at 18.58%. The company is seeing steady operational improvements, with occupancy (excluding the new Raipur facility) rising to 55% and ARPOB standing at ₹38,797. A key highlight is the Raipur facility, which reduced its quarterly EBITDA loss to ₹2.5 crores and is expected to break even within the next six months. Management remains committed to expanding its capacity to 1,000 beds by 2027, with the Jamshedpur project currently on track.
முக்கிய அம்சங்கள்
9M FY26 Revenue grew 12.12% YoY to ₹350.5 crores, while Q3 revenue surged 16.81% YoY.EBITDA for 9M FY26 stood at ₹65.1 crores with an 18.58% margin; PAT was ₹27.6 crores.Raipur facility EBITDA loss narrowed to ₹2.5 crores in Q3, with monthly breakeven expected in 6 months.Salt Lake hospital occupancy improved to 63%, supported by over 750 robotic-enabled surgical procedures.Company on track to reach 1,000-bed capacity by 2027, including the upcoming 150-bed Jamshedpur facility.
👀 கவனிக்க வேண்டியவை
Investors should monitor the Raipur facility's path to profitability over the next two quarters as it will significantly boost overall margins. The company remains a strong growth play in the underserved Eastern India healthcare market.
GPT Healthcare Q3 Revenue Up 17% to ₹122 Cr; PAT Declines 23.5% Amid Margin Pressure
GPT Healthcare reported a 16.81% YoY increase in Q3 FY26 revenue to ₹121.6 crore, supported by higher patient volumes and a stronger specialty mix. However, the company faced significant margin contraction, with EBITDA margins falling to 18.20% from 22.23% in the previous year's quarter. Consequently, Profit After Tax (PAT) for Q3 FY26 declined by 23.5% YoY to ₹9.4 crore. For the nine-month period (9M FY26), revenue grew 12.12% to ₹350.5 crore, while PAT fell 25.32% to ₹27.6 crore, reflecting the impact of scaling new facilities like Raipur.
முக்கிய அம்சங்கள்
Q3 FY26 Total Revenue grew 16.81% YoY to ₹121.6 crore, while 9M FY26 revenue rose 12.12% to ₹350.5 crore.Profit After Tax (PAT) for Q3 FY26 declined 23.5% YoY to ₹9.4 crore from ₹12.1 crore.EBITDA margins contracted to 18.20% in Q3 FY26 compared to 22.23% in the corresponding quarter last year.Average Revenue Per Occupied Bed (ARPOB) for 9M FY26 stood at ₹38,797 with an overall occupancy of 45%.Company completed 750+ robotic surgeries at ILS Salt Lake and commissioned CTVS at ILS-Dum Dum.
👀 கவனிக்க வேண்டியவை
Investors should be cautious as the sharp decline in profitability and margins may weigh on the stock price in the short term. Monitor the ramp-up of the Raipur facility and the progress of the Jamshedpur project to see if operating leverage improves margins in future quarters.
GPT Healthcare Q3FY26 Revenue up 17.5% YoY to ₹120 Cr; PAT drops 23.5% to ₹9.37 Cr
GPT Healthcare reported a 17.5% YoY growth in revenue from operations to ₹120.16 crore for Q3FY26. However, net profit declined significantly by 23.5% YoY to ₹9.37 crore, primarily due to a sharp rise in operating and depreciation expenses. On a nine-month basis, while revenue grew to ₹346.18 crore, profit after tax fell from ₹37.03 crore to ₹27.65 crore. The company's margins were pressured by a 29% YoY increase in other expenses and a 52% jump in depreciation costs.
முக்கிய அம்சங்கள்
Revenue from operations grew 17.5% YoY to ₹12,015.81 lakhs in Q3FY26.Net Profit (PAT) declined by 23.5% YoY to ₹936.83 lakhs from ₹1,224.61 lakhs in the same quarter last year.Other expenses surged 28.9% YoY to ₹5,448.77 lakhs, significantly impacting operating margins.Depreciation and amortization expenses increased by 52.3% YoY to ₹710.99 lakhs.Nine-month (9MFY26) PAT stands at ₹2,765.45 lakhs, down 25.3% compared to ₹3,703.17 lakhs in 9MFY25.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as the company is experiencing significant margin compression despite healthy top-line growth. It is critical to monitor management's explanation for the surge in 'Other expenses' and the impact of new capacity on depreciation.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
